Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
The ALIGN Study
A Phase 3 Study of Atrasentan in IgA Nephropathy
Brief Description
The ALIGN study is testing atrasentan, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy.
Trial Physician / Study Coordinator
Ahmadshah Mirkhel
EmailSite Name
Nephrology Associates Of Northern Virginia
13135 Lee Jackson Memorial Hwy #135, Fairfax, VA 22033
Sponsor
Chinook Therapeutics
Study Drug
Atrasentan
Estimated enrollment
320
Estimated end date
December 2025
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
The ALIGN Study
A Phase 3 Study of Atrasentan in IgA Nephropathy
Brief Description
The ALIGN study is testing atrasentan, an investigational medication that has the potential to reduce proteinuria and preserve kidney function in patients with IgA nephropathy.
Trial is for people with
Iga Nephropathy (IgAN)
Study Goal
The goal of the study is to determine if atrasentan reduces proteinuria and preserves kidney function in patients with IgAN.
What is involved for the Patient?
Patients will participate for about 2 ½ years and will receive either atrasentan or placebo.
About the drug or intervention
Atrasentan is a tablet taken orally once a day.